KR20240151767A - 티에노피롤로트리아진 화합물, 이의 제조 및 이의 치료 용도 - Google Patents
티에노피롤로트리아진 화합물, 이의 제조 및 이의 치료 용도 Download PDFInfo
- Publication number
- KR20240151767A KR20240151767A KR1020247027615A KR20247027615A KR20240151767A KR 20240151767 A KR20240151767 A KR 20240151767A KR 1020247027615 A KR1020247027615 A KR 1020247027615A KR 20247027615 A KR20247027615 A KR 20247027615A KR 20240151767 A KR20240151767 A KR 20240151767A
- Authority
- KR
- South Korea
- Prior art keywords
- acetamide
- isopropyl
- triazin
- pyrrolo
- oxothieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22315036.8 | 2022-02-21 | ||
| EP22315036 | 2022-02-21 | ||
| PCT/EP2023/054138 WO2023156643A1 (en) | 2022-02-21 | 2023-02-20 | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240151767A true KR20240151767A (ko) | 2024-10-18 |
Family
ID=81326677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247027615A Pending KR20240151767A (ko) | 2022-02-21 | 2023-02-20 | 티에노피롤로트리아진 화합물, 이의 제조 및 이의 치료 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250129091A1 (https=) |
| EP (1) | EP4482841A1 (https=) |
| JP (1) | JP2025506729A (https=) |
| KR (1) | KR20240151767A (https=) |
| CN (1) | CN118843632A (https=) |
| AU (1) | AU2023222186A1 (https=) |
| CA (1) | CA3244475A1 (https=) |
| CO (1) | CO2024010803A2 (https=) |
| IL (1) | IL314781A (https=) |
| MX (1) | MX2024010216A (https=) |
| WO (1) | WO2023156643A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116375728B (zh) * | 2021-12-31 | 2025-06-10 | 成都赜灵生物医药科技有限公司 | 噻吩吡咯并三嗪酮类化合物及其用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210038877A (ko) * | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| JP2023523418A (ja) * | 2020-04-23 | 2023-06-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３の阻害剤としての三環式化合物 |
-
2023
- 2023-02-20 JP JP2024549135A patent/JP2025506729A/ja active Pending
- 2023-02-20 IL IL314781A patent/IL314781A/en unknown
- 2023-02-20 CN CN202380021421.XA patent/CN118843632A/zh active Pending
- 2023-02-20 EP EP23705039.8A patent/EP4482841A1/en active Pending
- 2023-02-20 WO PCT/EP2023/054138 patent/WO2023156643A1/en not_active Ceased
- 2023-02-20 MX MX2024010216A patent/MX2024010216A/es unknown
- 2023-02-20 AU AU2023222186A patent/AU2023222186A1/en active Pending
- 2023-02-20 US US18/834,987 patent/US20250129091A1/en active Pending
- 2023-02-20 CA CA3244475A patent/CA3244475A1/en active Pending
- 2023-02-20 KR KR1020247027615A patent/KR20240151767A/ko active Pending
-
2024
- 2024-08-08 CO CONC2024/0010803A patent/CO2024010803A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314781A (en) | 2024-10-01 |
| US20250129091A1 (en) | 2025-04-24 |
| JP2025506729A (ja) | 2025-03-13 |
| MX2024010216A (es) | 2024-09-02 |
| CO2024010803A2 (es) | 2024-08-20 |
| CN118843632A (zh) | 2024-10-25 |
| EP4482841A1 (en) | 2025-01-01 |
| CA3244475A1 (en) | 2023-08-24 |
| WO2023156643A1 (en) | 2023-08-24 |
| AU2023222186A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023263450B2 (en) | Pyridazine compounds for inhibiting nlrp3 | |
| AU2020421426A1 (en) | RORγt inhibitor, preparation method thereof and use thereof | |
| TWI826509B (zh) | 作為vanin抑制劑之雜芳族化合物 | |
| JP6908623B2 (ja) | テトラヒドロイソキノリン誘導体 | |
| JP7101685B2 (ja) | 新規ｊａｋキナーゼ阻害剤としての二環式アミン | |
| JP7417594B2 (ja) | Ｔｒｋ阻害剤としてのイミダゾ［１，２－ｂ］ピリダジン | |
| WO2011050284A1 (en) | Pyrazolylpyridine antiviral agents | |
| KR20240151767A (ko) | 티에노피롤로트리아진 화합물, 이의 제조 및 이의 치료 용도 | |
| US20180179188A1 (en) | Substituted piperazine compounds and methods of use and use thereof | |
| CA3120037A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| WO2020011147A1 (en) | RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE | |
| WO2022251280A1 (en) | Compounds selective for jak1 and methods of use | |
| KR20210035225A (ko) | Trk 억제제로서 이미다조[1,2-b]피리다진 유도체 | |
| CA3203129A1 (en) | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease | |
| CA3028824C (en) | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | |
| EP4463450A1 (en) | Fused heteroaryl hydroxamates as sting agonists | |
| KR20230134499A (ko) | Irak4 억제제로서의 2h-인다졸 유도체 및 질환의 치료에서의그의 용도 | |
| BR112020026434A2 (pt) | derivados de amino-pirimidonila, um processo para sua preparação e composições farmacêuticas contendo-os | |
| WO2025155786A1 (en) | Bicyclic tyrosine kinase 2 inhibitors and uses thereof | |
| HK40083400A (en) | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| WO2025049774A1 (en) | (e)-2-(benzylamino)-n-(3-(methylsulfonyl)allyl)-benzamide derivatives and similar compounds as jak1 inhibitors for the treatment of inflammatory diseases, autoimmune diseases or cancer | |
| WO2024222807A1 (en) | Novel macrocyclic heteroaryl derivatives as kinase inhibitors | |
| EA047455B1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-а]ПИРИДИНИЛА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| KR20260009847A (ko) | 티아졸계 유도체 억제제, 이의 제조 방법 및 응용 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |